Daily Stock Analysis, ATRS, Antares Pharma Inc, priceseries

Antares Pharma Inc. Daily Stock Analysis
Stock Information
Open
2.85
Close
2.81
High
2.89
Low
2.79
Previous Close
2.82
Daily Price Gain
-0.01
YTD High
3.10
YTD High Date
Apr 5, 2017
YTD Low
1.83
YTD Low Date
Jan 27, 2017
YTD Price Change
0.50
YTD Gain
21.65%
52 Week High
3.10
52 Week High Date
Apr 5, 2017
52 Week Low
0.79
52 Week Low Date
May 19, 2016
52 Week Price Change
1.80
52 Week Gain
178.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 22. 2016
1.04
Feb 3. 2016
1.11
8 Trading Days
6.34%
Link
LONG
May 31. 2016
0.97
Jun 10. 2016
1.03
8 Trading Days
6.37%
Link
LONG
Aug 19. 2016
1.12
Aug 29. 2016
1.22
6 Trading Days
8.86%
Link
LONG
Sep 14. 2016
1.36
Oct 4. 2016
1.68
14 Trading Days
23.21%
Link
LONG
Dec 13. 2016
2.04
Dec 29. 2016
2.26
11 Trading Days
10.99%
Link
LONG
Mar 13. 2017
2.49
Mar 21. 2017
2.67
6 Trading Days
7.16%
Link
Company Information
Stock Symbol
ATRS
Exchange
NasdaqCM
Company URL
www.antarespharma.com
Company Phone
609-359-3020
CEO
Robert F. Apple
Headquarters
New Jersey
Business Address
100 PRINCETON SOUTH, SUITE 300, EWING, NJ 08628
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Instruments & Supplies
CIK
0001016169
About

Antares Pharma, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. It has one operating segment, drug delivery, which includes the development of injection devices and injection based pharmaceutical products as well as transdermal gel products. The company was founded in 1979 and is headquartered in Ewing, NJ.

Description

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It also offers Elestrin gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; and Gelnique, an oxybutynin gel product for the treatment of overactive bladder. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes; VIBEX QuickShot (QS) auto injectors for reducing risk of preterm birth; VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency; and Vibex QS M for the treatment of CNS indication. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals Inc. and Ferring B.V.; JCR Pharmaceuticals Co., Ltd.; Teva Pharmaceutical Industries, Ltd.; Actavis plc; Meda Pharmaceuticals, Inc.; and AMAG Pharmaceuticals, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.